Literature DB >> 31176555

Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.

Jenny L Frazer1, C Elizabeth Hook2, Helen C Addley3, Claire R Jackson4, John A Latimer1, James C Nicholson5, Matthew J Murray6.   

Abstract

Immature teratomas (IT) are rare and recurrences uncommon. A 12-year-old female with grade 3 (high-grade) ovarian IT underwent surgical resection but experienced early recurrences; the first was treated with surgery but the second was metastatic and managed with chemotherapy, resulting in growing-teratoma-syndrome and need for further surgery. She now remains well in uneventful clinical follow-up. We believe chemotherapy could be reserved for very carefully selected recurrent IT cases, which may alter the natural history of disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Germ cell tumor; Growing teratoma syndrome; Gynecologic oncology; Immature teratoma; Ovarian; Pediatric oncology; Surgery

Mesh:

Substances:

Year:  2019        PMID: 31176555     DOI: 10.1016/j.ygyno.2019.05.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Growing Teratoma Syndrome with Synchronous Gliomatosis Peritonei during Chemotherapy in Ovarian Immature Teratoma: A Case Report and Literature Review.

Authors:  Sijian Li; Na Su; Congwei Jia; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Curr Oncol       Date:  2022-09-04       Impact factor: 3.109

2.  An Uncommon Recurrent Metastasis of Ovarian Immature Teratoma to the Small Bowel.

Authors:  Mohammad Al-Hazaimeh; Mahmoud Jaradat; Mohammed El-Sadoni; Tamara Smadi; Ruba Shannaq; Omar Bani Hani; Ahmad Alhesa; Nisreen Abu Shahin; Tareq Saleh
Journal:  Case Rep Oncol       Date:  2021-12-27

Review 3.  Pediatric growing teratoma syndrome of the ovary: A case report and review of the literature.

Authors:  Takanori Oyama; Takuo Noda; Kana Washio; Akira Shimada
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.